Vivani Medical
Clinical-stage implants delivering six-month long-term medications
Accounting Manager
Three days on-site per week are required; travel may be required.
About the job
- A Bachelor's degree in Accounting, Finance, or a related field is required.
- At least 5–8 years of progressive accounting experience is required.
- Strong understanding of United States Generally Accepted Accounting Principles, month-end close, consolidations, and public company accounting environments is required.
- Experience supporting or managing Sarbanes-Oxley compliance and internal controls is required.
- Strong analytical, organizational, and problem-solving skills are required.
- Excellent communication and interpersonal abilities are required.
- Ability to work independently, prioritize effectively, and manage multiple responsibilities simultaneously is required.
- Demonstrated proactive ownership and follow-through are required.
- Previous experience with multiple finance and accounting software-as-a-service platforms is required.
- Must be legally authorized to work in the United States without company sponsorship.
- Manage and review key accounting processes, journal entries, reconciliations, and supporting schedules.
- Oversee monthly, quarterly, and annual close activities to ensure timely and accurate financial reporting.
- Review and support accounting processes for procure-to-pay operations, cash and treasury activity, fixed assets, prepaid expenses, accrued liabilities, intercompany activity and consolidations, and equity and stock compensation accounting.
- Support preparation and review of financial statement support schedules and disclosure tie-outs.
- Assist with Securities and Exchange Commission reporting support activities, including Forms 10-Q, 10-K, and related disclosures.
- Ensure accounting documentation is complete, organized, and audit-ready.
- Support implementation, enhancement, enforcement, and ongoing monitoring of Sarbanes-Oxley controls and compliance processes.
- Maintain and improve accounting policies, procedures, and process documentation.
- Coordinate walkthroughs, testing support, remediation tracking, and control evidence retention.
- Help establish scalable internal control frameworks aligned with the Committee of Sponsoring Organizations framework and public company requirements.
- Monitor compliance with delegated authority requirements, approval workflows, and accounting policies.
- Perform in-house Sarbanes-Oxley internal audit activities, including control testing, documentation review, identification of control gaps, and remediation follow-up.
- Evaluate operational and financial process risks and recommend control improvements.
- Assist with preparation for external audit and Sarbanes-Oxley auditor review activities.
- Educate and support business partners on accounting guidance, procurement requirements, internal controls, and best practices.
- Serve as a resource to operational teams regarding accounting procedures and documentation expectations.
- Manage and coordinate external consultants and third-party accounting resources as needed.
- Support implementation of new accounting systems, process automation initiatives, and operational improvements.
- Participate in special projects, technical accounting analyses, and ad hoc finance initiatives.
- Assist with policy development and accounting process standardization.
- CPA license.
- Public company accounting experience.
- Experience supporting Securities and Exchange Commission reporting processes.
- Experience performing internal audit or Sarbanes-Oxley testing activities.
- Experience managing external consultants or outsourced accounting resources.
- Experience with NetSuite, QuickBooks, Bill.com, Gusto, and Expensify.
- Experience within biotech, medtech, life sciences, or other regulated industries.
About the company
Vivani Medical develops long-term subdermal drug implants that deliver medications for six months or longer using its NanoPortal platform. Implants placed under the skin release a steady dose to improve medication adherence and reduce the need for daily injections. The company’s initial program targets GLP-1 therapies, including NPM-139 for obesity and NPM-133 for type 2 diabetes. Its goal is to improve chronic disease management by providing reliable, long-acting treatment options with implant-based delivery.
Company Size
11-50
Company Stage
IPO
Headquarters
Alameda, California
Founded
2003
Get referred to Vivani Medical
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 13, 2026 second-quarter results showed completed dosing and Phase 2 preparations.
- The Cortigent spinout can reduce Vivani spending and sharpen management on NPM-139.
- If SLIM-1 succeeds, Vivani can file IND and launch Phase 2 in 2027.
What critics are saying
- Vivani ended June 30, 2026 with $20.8 million cash against continued clinical burn.
- SLIM-1 top-line data arrives November 2026; failure would cripple Phase 2 plans.
- Cortigent's reverse-merger still needs financing and approvals; collapse strands Vivani with extra overhead.
What makes Vivani Medical unique
- NanoPortal implants target once- or twice-yearly semaglutide delivery, unlike weekly injections.
- August 6, 2026 SLIM-1 fully dosed 20 participants ahead of schedule.
- July 7, 2026 Novo Nordisk agreed to evaluate NPM-139, validating the platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Life Insurance
Disability Insurance
Home Office Stipend
Commuter Benefits
Company News
Vivani Medical announces participation in upcoming investor conferences. ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal(TM) technology, today announced its planned participation in two upcoming investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth Conference September 10, 2026 Metropolitan Club New York, New York H.C. Wainwright 28th Annual Global Investment Conference September 14-16, 2026 Lotte New York Palace Hotel New York, New York A pre-recorded company presentation for the H.C. Wainwright conference will be available for viewing starting at 7 a.m. Eastern Time on September 11, 2026, at the following link: https://journey.ct.events/view/cd7ac7c4-e1df-4951-ab94-1fb0727c8270. About Vivani Medical, Inc. Leveraging its proprietary NanoPortal(TM) platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that are used in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani's expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the "SEC") including the factors described in Vivani's most recent Quarterly Report on Form 10-Q filed with the SEC on August 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer [email protected] (415) 506-8462 Investor and Media Relations Contact: Jami Taylor Investor and Media Relations Advisor [email protected] (415) 506-8462
Vivani Medical plans to begin its first human trial of a semaglutide implant in August, focusing initially on safety, tolerability, and early weight-loss signals. The company recently signed an agreement with Novo Nordisk to evaluate its NanoPortal implant technology. CEO Adam Mendelsohn called the Novo Nordisk deal a significant milestone, signalling big pharma interest in implant-based GLP-1 delivery. The implant is designed to improve adherence through infrequent dosing, potentially once or twice yearly, whilst allowing rapid treatment cessation through removal. Vivani's lead programme, NPM-139, delivers semaglutide — the active ingredient in Ozempic and Wegovy — for six to 12 months. The company aims to address issues with missed doses and treatment discontinuation by guaranteeing adherence and delivering stable drug levels over time.
Vivani Medical to present at the Emerging Growth Conference on July 15, 2026. ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) - Vivani Medical, Inc. (NASDAQ: VANI) (the "Company" or "Vivani"), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or twice-yearly administration, today announced that it will present at the Emerging Growth Conference on July 15, 2026. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. Vivani CEO Adam Mendelsohn, Ph.D., will deliver a company update and may subsequently open the floor to questions. Please submit questions in advance to [email protected]. Vivani will be presenting at 4:10 p.m. Eastern Time. Please register at the following link to attend the conference and receive any updates released in follow up to the Vivani presentation: https://goto.webcasts.com/starthere.jsp?ei=1764180&tp_key=8f1191cdb2&sti=vani An archived webcast will be made available after the conference on EmergingGrowth.com and on the Emerging Growth YouTube channel. About Vivani Medical, Inc. Leveraging its proprietary NanoPortal(TM) platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that are used in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission including the factors described in Vivani's most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer [email protected] (415) 506-8462 Investor and Media Relations Contact: Jami Taylor Investor and Media Relations Advisor [email protected] (415) 506-8462
Vivani Medical enters into agreement with Novo Nordisk to evaluate NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Nprepared by Vivaniovo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants. ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company's semaglutide drug implant. NPM-139, which utilizes Vivani's NanoPortal platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology associated with this agreement. Adam Mendelsohn, PhD, CEO of Vivani Medical. Adam Mendelsohn, PhD, CEO of Vivani Medical, holds the miniature semaglutide (GLP-1) implant designed for once- or twice-yearly administration. Adam Mendelsohn, Ph.D., Vivani President and CEO, stated: "The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary." Separately, Vivani expects to initiate a Phase 1, randomized, first-in-human study evaluating the NPM-139 semaglutide implant, with Wegovy(R) injections as an active comparator, in mid-2026. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM-139 to support the initiation of a Phase 2 dose-ranging study pending successful results of the Phase 1 study. About Vivani Medical, Inc. Leveraging its proprietary NanoPortal platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that are used in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from its expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission including the factors described in Vivani's most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer [email protected] (415) 506-8462 Investor and Media Relations Contact: Jami Taylor Investor and Media Relations Advisor [email protected] (415) 506-8462 GlobeNewswire Distribution ID 9758110
Vivani Medical enters into agreement with Novo Nordisk to evaluate NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. July 07, 2026 Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) - Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company's semaglutide drug implant. NPM-139, which utilizes Vivani's NanoPortal(TM) platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani's proprietary NanoPortal technology associated with this agreement. Adam Mendelsohn, Ph.D., Vivani President and CEO, stated: "The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary." Separately, Vivani expects to initiate a Phase 1, randomized, first-in-human study evaluating the NPM-139 semaglutide implant, with Wegovy(R) injections as an active comparator, in mid-2026. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM-139 to support the initiation of a Phase 2 dose-ranging study pending successful results of the Phase 1 study. About Vivani Medical, Inc. Leveraging its proprietary NanoPortal(TM) platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that are used in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from its expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission including the factors described in Vivani's most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer [email protected] (415) 506-8462 Investor and Media Relations Contact: Jami Taylor Investor and Media Relations Advisor [email protected] (415) 506-8462 AAPR aggregates press releases and media statements from around the world to assist its news partners with identifying and creating timely and relevant news. All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.